# Research progress on targeted delivery of proteasome inhibitor nanoparticles for the treatment of multiple myeloma

## TL;DR

This paper reviews progress in using nanoparticle-based targeted delivery of proteasome inhibitors to treat multiple myeloma, addressing challenges like short drug half-life and toxicity.

## Contribution

A comprehensive review of nanocarrier mechanisms for proteasome inhibitors in multiple myeloma treatment.

## Key findings

- Nanoparticles improve drug solubility and circulation time for proteasome inhibitors.
- Targeted delivery reduces drug resistance and adverse effects in multiple myeloma patients.
- Current research highlights the potential of nanocarriers for more effective MM therapy.

## Abstract

近年来，蛋白酶体抑制剂广泛应用于多发性骨髓瘤（MM）的治疗，展现出良好的应用价值，然而，这类药物在临床应用中仍面临诸多挑战，如循环半衰期短、水溶性差、患者耐药及发生严重不良事件。纳米靶向给药凭借其独特优势，有望成为解决上述问题的有效途径之一。本文对国内外蛋白酶体抑制剂的纳米靶向给药机制及其用于MM治疗的研究进展进行梳理，以期为相关领域的研究者提供参考。